In ASCVD patients, is LDL <70 mg/dL good enough — or should we push harder to <55?
Ez-PAVE trial (NEJM) delivers a clear answer: intensive targeting cuts major events by 33%.
Practice-changing for secondary prevention?
🚨 Cardiologists: Old rule = tolerate low-normal K+ in ICD pts to dodge hyperK fears.
New POTCAST reality (NEJM): Push to high-normal (4.5–5.0 mmol/L) → ~31% ↓ in VT/ICD shocks, arrh/HF hosp, or death.
Cheap K+ boost or MRA tweak = big arrhythmia protection.
#Cardiology#EPeeps
TOP-CABG trial shows 3-month ticagrelor-based DAPT post-CABG is NONINFERIOR to 12 months for saphenous vein graft patency — AND slashes clinically relevant bleeding (8.3% vs 13.2%)! 🫀🩸
Would you shorten DAPT in your next CABG patient? Drop thoughts below!
#DAPT#CABG
BREAKING HF STRATEGY UPDATE 📢
A single polypill for HFrEF significantly improved heart function, symptoms, quality of life & cut hospital visits vs separated meds.
#heartfailure#Cardiology#Medicine#pharmacy
1️⃣
🚨 LANDMARK PRIMARY PREVENTION BREAKTHROUGH 🧠💥
A PCSK9 inhibitor has now been shown to reduce first heart attack & stroke risk in high-risk patients with NO prior MI or stroke.
NEW CARDIOLOGY DISCOVERY
Patients with chest pain and normal coronary angiograms may still have true angina from microvascular disease — detectable with stress cardiac MRI! 🧠
This may change how we approach “normal cath results.”
#Cardiology#Angina#aha#HeartHealth